Funding Digital Therapeutics – Who counts?

Digital therapeutics, when created empathetically to patients and health care professionals (HCPs), can show significant value to all stakeholders in the healthcare pathway [1]. A question at a recent NHS conference prompted an important question: if pharma is funding these innovations with a commercial motivation, how do you ensure equality in access to digital therapeutics?…

Highlights from NICE 2018 – Tackling Antimicrobial Resistance Globally and Locally

pH Associates were delighted to meet with current and former clients at the NICE Conference #NICEConf18 last week and to have the opportunity to attend some thought-provoking breakout sessions.  Of particular interest was a topical session focused on ‘Tackling Antimicrobial Resistance Globally and Locally’, with Nick Crabb (Programme Director, Scientific Affairs, NICE), Susan Hopkins (Chair…

Resource use data to demonstrate the value of your brand?

Do you need resource use data to provide supporting evidence that demonstrates the value of your brand? Despite offering clear benefits in terms of satisfying unmet clinical need, many new interventions face barriers to adoption within healthcare settings due to resourcing challenges beyond acquisition cost.  pH Associates specialise in the design and implementation of non-interventional…

Is your patient centred outcome (PCO) work truly patient centred?

At pH Associates we have worked successfully in collaboration with patient organisations across a number of different disease areas, working together throughout study development, rollout and publication. A recent document, published by European Federation of Pharmaceutical Industries and Associations (EFPIA) called “Working together with patient groups”, has sparked our interest. This document has been designed…